AEON
AEON Biopharma, Inc.
NYSE MKT: AEON · HEALTHCARE · BIOTECHNOLOGY
$0.95
-3.02% today
Updated 2026-04-29
Market cap
$24.16M
P/E ratio
—
P/S ratio
97.16x
EPS (TTM)
$-3.95
Dividend yield
—
52W range
$0 – $1
Volume
0.1M
AEON Biopharma, Inc. (AEON) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.36M | $2.52M | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -25.0% | -100.0% | — | — | — | — |
| Cost of revenue | $1000.00 | $0.00 | — | — | — | — | $78000.00 |
| Gross profit | $3.36M | $2.52M | — | — | — | — | $-78000.00 |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — |
| R&D | $4.81M | $7.32M | $25.73M | $34.75M | $33.05M | $14.18M | $4.29M |
| SG&A | $46.04M | $11.59M | $11.15M | $13.68M | — | $13.64M | $12.21M |
| Operating income | $-53.97M | $-16.39M | $-65.85M | $-48.43M | $-348.09M | $72.98M | $-16.90M |
| Operating margin | -1607.6% | -650.8% | — | — | — | — | — |
| EBITDA | $-47.49M | $-15.51M | $-36.88M | $-48.36M | $-52.74M | $-27.73M | $-16.82M |
| EBITDA margin | -1414.8% | -616.1% | — | — | — | — | — |
| EBIT | $-48.37M | $-16.39M | $-36.88M | $-48.43M | $-52.84M | $-27.82M | $-16.90M |
| Interest expense | $7.47M | $15000.00 | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $172.92M | $-32.91M | $-55.64M | $-52.56M | $-384.63M | $42.01M | $-39.22M |
| Net income growth (YoY) | — | -119.0% | -69.0% | +5.5% | -631.9% | +110.9% | -193.4% |
| Profit margin | 5151.0% | -1307.1% | — | — | — | — | — |